200 related articles for article (PubMed ID: 15228258)
1. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
Rijal S; Chappuis F; Singh R; Bovier PA; Acharya P; Karki BM; Das ML; Desjeux P; Loutan L; Koirala S
Trans R Soc Trop Med Hyg; 2003; 97(3):350-4. PubMed ID: 15228258
[TBL] [Abstract][Full Text] [Related]
2. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
3. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
4. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
5. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).
Uranw S; Ostyn B; Rijal A; Devkota S; Khanal B; Menten J; Boelaert M; Rijal S
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1433. PubMed ID: 22206030
[TBL] [Abstract][Full Text] [Related]
7. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
Diro E; Lynen L; Mohammed R; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 May; 8(5):e2875. PubMed ID: 24854196
[TBL] [Abstract][Full Text] [Related]
8. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.
Rijal S; Bhandari S; Koirala S; Singh R; Khanal B; Loutan L; Dujardin JC; Boelaert M; Chappuis F
Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):225-9. PubMed ID: 19726065
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
10. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
[TBL] [Abstract][Full Text] [Related]
11. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
Perry MR; Prajapati VK; Menten J; Raab A; Feldmann J; Chakraborti D; Sundar S; Fairlamb AH; Boelaert M; Picado A
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003518. PubMed ID: 25730310
[TBL] [Abstract][Full Text] [Related]
12. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory study of kala-azar in children in Nepal.
Singh K; Singh R; Parija SC; Faridi MM; Bhatta N
J Trop Pediatr; 1999 Apr; 45(2):95-7. PubMed ID: 10341503
[TBL] [Abstract][Full Text] [Related]
14. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
[TBL] [Abstract][Full Text] [Related]
15. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
Veeken H; Ritmeijer K; Seaman J; Davidson R
Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
[TBL] [Abstract][Full Text] [Related]
17. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
[TBL] [Abstract][Full Text] [Related]
20. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
